(NASDAQ: AVXL) Anavex Life Sciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.76%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.9%.
Anavex Life Sciences's earnings in 2026 is -$46,377,000.On average, 5 Wall Street analysts forecast AVXL's earnings for 2026 to be -$43,744,833, with the lowest AVXL earnings forecast at -$43,780,572, and the highest AVXL earnings forecast at -$43,155,136. On average, 4 Wall Street analysts forecast AVXL's earnings for 2027 to be $115,741,538, with the lowest AVXL earnings forecast at $111,202,654, and the highest AVXL earnings forecast at $119,145,701.
In 2028, AVXL is forecast to generate $327,174,898 in earnings, with the lowest earnings forecast at $314,344,510 and the highest earnings forecast at $336,797,689.